Congress backs drug price cap tied to lowest international rates
H.Res. 928 — Affirming support for most-favored-Nation drug pricing for United States patients. · Filed by Debbie Dingell (D-MI) · 1 cosponsor · Introduced Dec 4, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This resolution expresses House support for 'most-favored-nation' drug pricing—a policy that would cap U.S. prescription drug prices at the lowest prices charged in other developed countries. It cites data showing Americans pay 2.78 times more for drugs than comparable nations and endorses President Trump's May 2025 executive order directing the administration to align U.S. drug prices with those in peer countries.
Why we flagged it
This is a non-binding resolution expressing congressional support for most-favored-nation drug pricing and Medicare negotiation as mechanisms to reduce prescription drug costs for U.S. patients. It is a messaging instrument aligned with executive policy, not a legislative mandate.
What the text implies
- Resolution endorses executive action without legislative authorization—affirms Trump's May 2025 executive order but does not grant new statutory authority or funding, leaving implementation details to executive discretion.
- Most-favored-nation pricing may face legal challenge from pharmaceutical manufacturers on constitutional grounds (takings clause, due process); resolution does not address implementation barriers or litigation risk.
The full analysis lists 4 implications of this text.
Who stands to gain
U.S. patients and consumers (reduced out-of-pocket drug costs); Medicare and Medicaid (lower drug expenditures); Employers and insurers (reduced pharmacy benefit costs)